Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
Relate News
5/26/2022
China's First Decision In A Case Initiated Under Its Patent Linkage Sy...
5/26/2022
USTR Releases Special 301 Report On IP Protection With Special Section...
5/26/2022
April Licensing Trends Show Chinese Biotechs Expanding Beyond Oncology...
5/26/2022
Ten Trends of China's Pharmaceutical Industry in 2021 (PharmCube)
5/26/2022
Henlius and Abbott Enter Semi-Exclusive License Deal for Rituximab and...
5/26/2022
Data Snapshot: Top 20 Domestic Class 1 New Drugs by Sales in 2021
5/26/2022
Pharma Trading Platform Yaoshibang Applies for Hong Kong IPO
5/25/2022
CDE Issues the Technical Guidelines for Pharmaceutical Research and Ev...
5/25/2022
Hanmi Launches High-blood Pressure Drug Meiyaping (Amosartan) in China
5/25/2022
Beijing Health Chief Fired Following Investigation
5/25/2022
State Council Issues Notice on Major Tasks for Deepening Healthcare Re...
5/25/2022
Real-World Evidence Is Becoming a Pivotal Component in Chinese Healthc...
5/24/2022
New Draft Implementing Regulations Propose Key Changes for Pharmaceuti...
5/24/2022
Vir and WuXi Bio Terminate COVID Antibody Agreement
5/24/2022
ImaginAb and Yantai DongCheng Enter License Deal to Commercialize CD8...
5/24/2022
CASI and Tianshi Enter Sublicense Deal for Anti-Cd38 mAb CID-103 in Au...
5/23/2022
CDE Issues the Generic Format and Writing Guidelines for Package Inser...
5/23/2022
CDE Issues the Technical Guidelines for Clinical Evaluation of Intrave...
5/23/2022
Fujifilm Completes Construction of Bioprocessing Innovation & Collabor...
5/23/2022
Novartis's Promacta Approved in China for Expanded Use in Children Ag...
5/23/2022
Sinohealth: Chinese Hospital Drug Sales Fell 4% in Q1/2022
5/23/2022
IQVIA: Chinese Hospital Drug Market Rose 4.2% in Q1/2021
5/23/2022
VerImmune and Fosun Pharma Enter Licensing Deal for Virus-inspired Pa...
5/23/2022
Biopharma in China: The Emerging Global Force of Domestic Suppliers
5/20/2022
U.S., European Firms Rethink China Investment After Lockdowns
5/20/2022
VerImmune and Fosun in Deal for VerImmune's ViP Platform as Novel Im...
5/20/2022
Couple Plead Guilty to Smuggling and Fraud Charges After Sending ‘mRN...
5/20/2022
Recent Executive Moves
5/20/2022
Drug R&D and Product Registration News Digest May 2022 (3)
5/19/2022
Chinese Courts Handled Over 640,000 IPR Cases in 2021
Page:
83
/
719
Total number of articles:
21546
:
[First]
[<<]
[81]
[82]
[83]
[84]
[85]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit